RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Notice of Annual General Meeting in Hansa Medical AB (publ)

2 May 2014, 08:00
Regulatory information
Shareholders in Hansa Medical AB (publ) are hereby given notice of the Annual General Meeting on June 3,  2014, 6:00 pm (18:00), to be held in the lecture theatre at the company’s premises on Scheelevägen 22 in Lund. Doors open at 5:30 pm (17:30). Light refreshments will be provided following the meeting.

The right to participate in the Annual General Meeting of shareholders is extended to those who are both entered in the share register, administered by Euroclear Sweden AB, as per May 27, 2014, and who have registered their intention to participate in the Annual General Meeting no later than 12 pm (12:00) on May 27, 2014. For a complete Notice of AGM (in Swedish only) including a proposed agenda, see below, or visit www.hansamedical.com.

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.